Result of AGM and Consolidation of Share Capital (3606C)

TIDMNGG

RNS Number : 3606C

NextGen Group PLC

30 April 2012

NextGen Group Plc

("NextGen" or "the Company")

Result of Annual General Meeting and Consolidation of Share Capital

NextGen Group plc (AIM: NGG), an AIM listed company providing biomarker discovery services and diagnostic assay development, announces that at the Company's Annual General Meeting, which was held today, all the resolutions proposed were duly passed with more than 99% in favour of each resolution.

Following shareholder approval at the AGM, the Company's ordinary share capital will be consolidated with effect from close of business tonight such that every 500 existing ordinary shares of 0.1p will be consolidated into one ordinary share of 50p. Accordingly there will be 14,493,578 ordinary 50p shares in issue and application has been made to AIM for 14,493,578 ordinary shares of 50p each to be admitted to trading on AIM with effect from 1 May 2012. The ISIN for the new ordinary shares of 50p each is GB00B7JRYW03.

The figure of 14,493,578 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.

For further details please contact:

NextGen Group

Klaus Rosenau, Chairman

[phone]

Seymour Pierce

Jonathan Wright, Nicola Marrin

[phone]

About NextGen

NextGen (AIM: NGG), the biomarker specialists, provide services to pharmaceutical and biotech companies globally. Using advanced techniques, such as Multiple Reaction Monitoring (MRM) mass spectrometry analysis, the Company is developing a portfolio of robust assays for testing clinical samples for drug safety and efficacy, and the development of personalized treatment for patients. NextGen Sciences' range of services, which include biomarker testing, discovery and assay development, are employed by its customers as a key part of the biomarker-based drug and diagnostic development process. For more information visit www.nextgensciences.com

NextGen Group PLC floated on the AIM market in London in December 2005 raising GBP2.4 million in an oversubscribed offering which included strong institutional investor support from Germany as well as in the UK. Further details relating to NextGen Group PLC and its products can be found at www.nextgensciences.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGFBLFXLZFZBBF